CELLDEX THERAPEUTICS, INC.

CLDX · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Market Data

Price $31.15 +0.42 (+1.37%)

Market Cap$2.05B

P/E Ratio—

EPS$—

52W High$31.85

52W Low$14.40

Beta1.07

Data from Finnhub · Updated Mar 10, 2026